

IN THE CLAIMS

Please amend the claims as follows:

Sub C1  
B1

1. [twice amended] A method for inhibiting metastasis of lymphoma in a mammal which comprises administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of F(ab')<sub>2</sub>, Fab', Fab and Fc.

B2

3. [amended] The method according to claim 2, wherein the preparation of IVIG or fragments thereof is administered at a dosage of 2 g/kg/month.

B3  
Sub C2

22. [amended] A method for treating lymphoma in a mammal which comprises subcutaneously administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of F(ab')<sub>2</sub>, Fab', Fab and Fc.

B4

24. [amended] A method for treating lymphoma in a mammal which comprises intracavitarily administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of F(ab')<sub>2</sub>, Fab', Fab and Fc.

Sub C3

25. [amended] A method for treating metastatic lymphoma in a mammal which comprises administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of F(ab')<sub>2</sub>, Fab', Fab and Fc, wherein the method further comprises subjecting the mammal to at least one other treatment modality selected from the group

consisting of immunotherapy, radiation therapy and surgery, and wherein the other treatment modality is administered prior to, during or after the administration of IVIG or fragments thereof.

Sub C3  
Pat Bcont

26. [amended] A method for treating metastatic Hodgkin's lymphoma in a mammal which comprises administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of F(ab')<sub>2</sub>, Fab', Fab and Fc, wherein the method further comprises subjecting the mammal to at least one other treatment modality.

27. [amended] The method according to claim 26 wherein the other treatment modality is selected from the group consisting of chemotherapy, immunotherapy, radiation therapy and surgery, and wherein the other treatment modality is administered prior to, during or after the administration of IVIG or fragments thereof.

Sub C4

28. [amended] A method for treating metastatic lymphoma in a mammal which comprises administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of F(ab')<sub>2</sub>, Fab', Fab and Fc, wherein the method further comprises surgically removing the lymphoma prior to, during or after the administration of the preparation of IVIG or fragments thereof.

Sub  
B4 C4  
D conc.

29. [amended] A method for treating metastatic lymphoma in a mammal which comprises administering to the mammal a preparation of fragments of IVIG selected from the group consisting of F(ab')<sub>2</sub>, Fab', Fab and Fc.
- 

#### Amendments

Applicants have amended claims 1, 22, 24, 25, 26, 28 and 29, which recite single chain immunoglobulins. Applicants have deleted this recitation in these claims, as suggested by the Examiner, so as to expedite allowance of the pending claims. Applicants believe that single chain immunoglobulins are fully enabled by the application as filed, and reserve the right to prosecute claims directed to methods of using single chain immunoglobulins in the inhibition of lymphoma metastasis and treatment of lymphoma in subsequent continuation applications.

Applicants have amended claims 25, 26, 28 and 29 to recite "metastatic" lymphoma. Applicants have added the "metastatic" limitation to expedite allowance of the pending claims, however, applicants believe that treatment of non-metastatic lymphoma is also patentable, and applicants reserve the right to prosecute claims directed to such subject matter in continuation applications.

Applicants have amended claims 3, 25 and 27 to insert the words "or fragments thereof" after IVIG (after the second "IVIG" in claim 25) so as to be clear in referring back to the antecent in each claim.